.
Introduction
e etiology of idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, is unclear. IIH occurs mainly in young obese women. Underlying and associated endocrinological abnormalities have been reported in numerous studies [1, 2] .
Diagnostic criteria for IIH include signs and symptoms that re�ect intracranial pressure (e.g., papilledema), documented elevated intracranial pressure with normal CSF composition, no evidence of mass, structural, or vascular lesion on MRI, MR venography, or contrast-enhanced CT, and no other cause of intracranial hypertension [1, 3] . Treatment is aimed mainly to prevent visual compromise and alleviate headaches. Acetazolamide, weight loss, and correction of underlying risk factors, including endocrinological abnormalities, are recommended. Some cases are refractory to medical intervention and require surgery (fenestration of the optic-nerve sheath or lumboperitoneal shunting) [4, 5] .
Women with IIH need all the help we can offer to aid them in �ghting obesity and endocrinological abnormalities in order to prevent visual compromise.
e polycystic ovary syndrome (PCOS) includes truncal obesity, menstrual irregularities, hyperandrogenism with hirsutism, acne, alopecia, and multiple ovarian follicular cysts. PCOS is characterized by several endocrine abnormalities, including increased conversion of androstenedione to estrone by stromal cells within adipose tissue [6, 7] . Insulin resistance is more common in PCOS [8, 9] .
ere are two main accepted systems for de�ning PCOS. According to the NIH criteria, two conditions have to be met: chronic anovulation and clinical or biochemical evidence of hyperandrogenism. Recently, the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) suggested new criteria for the de�nition of PCOS. is is now de�ned as the presence of any two of the following conditions: (i) polycystic ovaries; (ii) oligo-/anovulation; (iii) clinical or biochemical evidence of hyperandrogenism [10] . ere is still debate regarding the most appropriate criteria [11] .
Glueck et al. [12, 13] reported an increased prevalence of PCOS in women with IIH, compared to the prevalence of PCOS in the general unselected population [14] .
Cosar et al. [15] found supporting evidence, using MRI and MR venography studies in women with PCOS and headache, that PCOS may facilitate the development of IHH.
We also suggest a screening questionnaire for the use of neurologists and ophthalmologists to aid in identifying women with IIH at risk for PCOS. Identifying women suspect of PCOS may aid those in need of further endocrinological workup and tailor treatment in this speci�c subgroup.
Methods

Participants.
We included all consecutive women of child-bearing age who met the diagnostic criteria for IIH followed at our hospital-based neuroophthalmology clinic between the years 2000-2005.
Study Protocol.
All consenting women included in this study �lledout a screening questionnaire (Appendix), aimed at identifying women at risk for PCOS. Women with suspected PCOS, based on the questionnaires' results, underwent testing for LH, FSH, testosterone, and 17-hydroxyprogesterone serum levels. e endocrinologist examined each patient suspect of PCOS, as well as the biochemical results, and classi�ed women as: (a) de�nite PCOS according to the NIH criteria if both conditions (anovulation and hyperandrogenism) were met. ese women were referred for US to con�rm polycystic ovaries and to serve as a base line for future followup. (b) Not meeting criteria for PCOS (only one criteria was met: oligo-/anovulation or clinical/biochemical hyperandrogenism), these patients were not referred to US.
e prevalence of PCOS in these women with IIH was compared with the reported prevalence of PCOS in the general population. We compared our results with a recent study, which is practically the largest communitybased prevalence study of PCOS in a Caucasian population, presented by March et al. [16] e parameters of age, gender, height, and weight were compared with both groups.
e study design was approved by the institutional review board. Patients were asked to provide their consent to the �lling of the questionnaire and to participate in study.
Statistical Analysis.
A comparison of the prevalence of PCOS in these women with IIH with the reported prevalence of PCOS in the general population [16] was performed using 2 test. A value of <0.05 was considered signi�cant.
Results
We included in the study consecutive Caucasian women, aged 18-50 years (mean = 34.49, SD = 10.37), who met the diagnostic criteria for IIH and were followed and treated at the neuroophthalmologic clinic, Rabin Medical Center, consecutive patients met the diagnostic criteria for IIH. Sixty four (47%) of them were women, two of whom deceased during the study and four refused to �ll out our questionnaire. Fiy-eight women were included in our study. Follow up ranged between 2 and 11 years (mean = 5; SD = 1.86).
Endocrinological abnormalities re�ecting PCOS are listed in Table 2 . e questionnaire revealed 22 of the 58 women (38%) as being at risk for PCOS (all had either oligo-/anovulation or clinical signs of hyperandrogenism). Aer reviewing the results of the questionnaires, blood tests and physical examination results, nine (9/58; 15.5%) had de�nite PCOS. US proved the presence of polycystic ovaries in all these women. 13 women (13/58; 8.7%) met only one criteria for PCOS (only oligo-/anovulation with no clinical or biochemical signs of hyperandrogenism). ey were not referred to US, however we could rule out PCOS according to the NIH criteria. Overall PCOS was ruled out in 49 (84%) women according to the NIH criteria.
When comparing the results of the current study to previous studies in the general population [16] , we found no difference in age, weight, and BMI parameters ( < in all parameters). When comparing the values found in our study to this previous report, having the same age, weight and BMI distribution, we found a signi�cantly higher prevalence of PCOS using the NIH criteria among the IHH study group (15.5%) compared to the general population (8.7%) [16] .
e positive predictive value of the proposed screening tool aimed to asses PCOS risk using the questionnaire, based on the comparison between the 22 women suspected as harboring PCOS, and the 9 found to have PCOS based on NIH criteria were 41% (9/22).
Ten (17.2%) patients were found to have various other endocrinological abnormalities: four (7%) with hypothyroidism and six (10%) with diabetes (three of them with de�nite PCOS). Hyperlipidemia was found in seven patients (12%).
Discussion
We examined the use of a new screening questionnaire to identify women with IIH at risk for PCOS for the use of neuroophthalmologists. is questionnaire found that 38% of women with IIH were at risk to have PCOS. Further blood tests and an endocrinologist examination helped to de�ne the diagnosis in 15.5% of patients included in the study. e positive predictive value of the proposed screening tool aimed to asses PCOS risk using the questionnaire was 41% (9/22). In addition, we found a signi�cantly higher prevalence of PCOS using the NIH criteria among the IHH study group (15.5%) compared to the general population.
e NIH diagnostic criteria for the diagnosis of PCOS were based on a consensus of experts, who concluded that women have PCOS if they present with the combination of chronic oligo-or anovulation and clinical or biochemical signs of hyperandrogenism. We based our questionnaire on their concept which maintains that androgen excess is a central feature of the disease.
Ultrasound and blood tests were not carried out on women who did not present with clinical symptoms of PCOS, as was also the case in other community studies of PCOS prevalence [14, 16] . ere may have been some women in this group who had hyperandrogenemia and polycystic ovaries but literature suggests that this is likely to be less than 1% of those with PCOS [14, 16] .
When comparing the results of the current study to previous studies in the general population having the same age and BMI distribution, we found a higher prevalence of PCOS using the NIH criteria among the IHH study group (15.5%) compared to the general population (8.7%) [16] . In three other previous studies using the NIH criteria, values were even lower standing at 6.5-6.8% [17] [18] [19] .
e results of this study con�rm a previously reported association between IIH and PCOS. Glueck et al. [12] reported that in 38 women with IIH, 15 (39%) were found to have PCOS. In another study of 65 women with IIH, 37 (57%) were found to have PCOS [13] . Knochenhauer et al. [14] stated that this prevalence of PCOS (39%-57%) in women with IIH is 5 to 8 times greater than the 7% prevalence of PCOS in the general unselected population.
Cosar et al. [15] performed MRI and MR venography studies of the brain and orbit in women with PCOS and headaches and found that PCOS and headache are promoters of IHH.
Similar to Glueck's results, we found an association between PCOS and IIH, but in our group the prevalence was only nearly twice as common (15.5%) than the 8.7% prevalence of PCOS in the general unselected population [16] .
On the basis of these �ndings, this study veri�es the argument of Glueck et al. e difference in prevalence may be a result of Glueck's use of the Rotterdam criteria for PCOS which are not as strict as the NIH criteria.
We also found that 10 (17.2%) patients had other endocrinological abnormalities. is has been documented before [20, 21] .
Our study group is relatively small in a bothersome way, but the group was compared to one of the most representative studies of PCOS prevalence in Caucasian women to date and was found comparative in terms of clinical parameters.
We suggest, for the �rst time, the use of a practical questionnaire that can be �lled out by the patients themselves, as an aid in detecting PCOS risk in a neurology or ophthalmology clinic setting. In fact, this questionnaire is not of paramount importance by itself, since the patients can also be directly asked in case the neuroophthalmologist remembers the potential association between PCO and IHH. We did not validate formally this questionnaire as well. However, we offer this tool in order to emphasize the necessity in diagnosing the associating diseases in order to improve the management of IHH patients. Addressing PCOS may help with the treatment of IIH by aiding weight loss and managing associated endocrinological abnormalities such as glucose intolerance and hyperandrogenism. We call for further study of the bene�t of PCOS treatment in the management of IIH. 
Con�ict of Interests
ere is no con�ict of interests related to this paper.
